Coherus Oncology, Inc. (CHRS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CHRS Revenue Growth
Revenue Breakdown (FY 2025)
CHRS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
CHRS Revenue Analysis (2014–2025)
As of May 7, 2026, Coherus Oncology, Inc. (CHRS) generated trailing twelve-month (TTM) revenue of $42.2 million, reflecting significant decline in growth of -76.5% year-over-year. The most recent quarter (Q4 2025) recorded $12.7 million in revenue, up 10.2% sequentially.
Looking at the longer-term picture, CHRS's 5-year compound annual growth rate (CAGR) stands at -38.4%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $475.8 million in 2020.
Revenue diversification analysis shows CHRS's business is primarily driven by Product and Service, Other (100%). With over half of revenue concentrated in Product and Service, Other, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PRGO (-3.6% YoY), AMRX (+8.0% YoY), and HCM (-1.4% YoY), CHRS has underperformed the peer group in terms of revenue growth. Compare CHRS vs PRGO →
CHRS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CHRSCurrent | $42M | -76.5% | -38.4% | -429.5% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 AMRX | $3.0B | +8.0% | +8.7% | -0.2% | |
 HCM | $630M | -1.4% | +25.2% | -6.9% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 MGNX | $150M | +0.8% | +8.9% | -48.7% |
CHRS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $42.2M | -84.2% | $-15,735,000 | -37.3% | $-181,134,000 | -429.5% |
| 2024 | $267.0M | +3.8% | $149.4M | 56.0% | $-111,667,000 | -41.8% |
| 2023 | $257.2M | +21.9% | $98.3M | 38.2% | $-203,199,000 | -79.0% |
| 2022 | $211.0M | -35.4% | $141.0M | 66.8% | $-256,880,000 | -121.7% |
| 2021 | $326.6M | -31.4% | $269.0M | 82.4% | $-263,858,000 | -80.8% |
| 2020 | $475.8M | +33.6% | $438.2M | 92.1% | $156.3M | 32.9% |
| 2019 | $356.1M | +22783.7% | $339.0M | 95.2% | $107.8M | 30.3% |
| 2018 | $1.6M | +0.0% | $-1,679,000 | -107.9% | $-204,416,000 | -13137.3% |
| 2017 | $1.6M | -99.2% | $-158,975,000 | -10216.9% | $-232,136,000 | -14918.8% |
| 2016 | $190.1M | +532.8% | $-64,334,000 | -33.8% | $-115,931,000 | -61.0% |
See CHRS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CHRS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CHRS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCHRS — Frequently Asked Questions
Quick answers to the most common questions about buying CHRS stock.
Is CHRS's revenue growth accelerating or slowing?
CHRS revenue declined -76.5% year-over-year, contrasting with the 5-year CAGR of -38.4%. TTM revenue fell to $42M. This reverses the prior growth trend.
What is CHRS's long-term revenue growth rate?
Coherus Oncology, Inc.'s 5-year revenue CAGR of -38.4% reflects the variable expansion pattern. Current YoY growth of -76.5% is below this long-term average.
How is CHRS's revenue distributed by segment?
CHRS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.